Literature DB >> 25531332

NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer.

S Kumar1, S Das1, S Rachagani1, S Kaur1, S Joshi1, S L Johansson2, M P Ponnusamy1, M Jain1,3, S K Batra1,3,4.   

Abstract

Pancreatic cancer (PC) is characterized by aberrant overexpression of mucins that contribute to its pathogenesis. Although the inflammatory cytokines contribute to mucin overexpression, the mucin profile of PC is markedly distinct from that of normal or inflamed pancreas. We postulated that de novo expression of various mucins in PC involves chromatin modifications. Analysis of chromatin modifying enzymes by PCR array identified differential expression of NCOA3 in MUC4-expressing PC cell lines. Immunohistochemistry analysis in tumor tissues from patients and spontaneous mouse models, and microarray analysis following the knockdown of NCOA3 were performed to elucidate its role in mucin regulation and overall impact on PC. Silencing of NCOA3 in PC cell lines resulted in significant downregulation of two most differentially expressed mucins in PC, MUC4 and MUC1 (P<0.01). Immunohistochemistry analysis in PC tissues and metastatic lesions established an association between NCOA3 and mucin (MUC1 and MUC4) expression. Spontaneous mouse model of PC (K-ras(G12D); Pdx-1cre) showed early expression of Ncoa3 during pre-neoplastic lesions. Mechanistically, NCOA3 knockdown abrogated retinoic acid-mediated MUC4 upregulation by restricting MUC4 promoter accessibility as demonstrated by micrococcus nuclease digestion (P<0.05) and chromatin immuno-precipitation analysis. NCOA3 also created pro-inflammatory conditions by upregulating chemokines like CXCL1, 2, 5 and CCL20 (P<0.001). AKT, ubiquitin C, ERK1/2 and NF-κB occupied dominant nodes in the networks significantly modulated after NCOA3 silencing. In addition, NCOA3 stabilized mucins post translationally through fucosylation by FUT8, as the knockdown of FUT8 resulted in the downregulation of MUC4 and MUC1 at protein levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25531332      PMCID: PMC4476953          DOI: 10.1038/onc.2014.409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology.

Authors:  Brian York; Chundong Yu; Jørn V Sagen; Zhaoliang Liu; Bryan C Nikolai; Ray-Chang Wu; Milton Finegold; Jianming Xu; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.

Authors:  Simon Rieder; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Anticancer Agents Med Chem       Date:  2011-06       Impact factor: 2.505

3.  Blocking core fucosylation of TGF-β1 receptors downregulates their functions and attenuates the epithelial-mesenchymal transition of renal tubular cells.

Authors:  Hongli Lin; Dapeng Wang; Taihua Wu; Cui Dong; Nan Shen; Yuan Sun; Yanling Sun; Hua Xie; Nan Wang; Lujuan Shan
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

4.  Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.

Authors:  Ying-Chih Liu; Hsin-Yung Yen; Chien-Yu Chen; Chein-Hung Chen; Ping-Fu Cheng; Yi-Hsiu Juan; Chung-Hsuan Chen; Kay-Hooi Khoo; Chong-Jen Yu; Pan-Chyr Yang; Tsui-Ling Hsu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

5.  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Authors:  Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

6.  Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Authors:  Rebecca E Nakles; Maddalena Tilli Shiffert; Edgar S Díaz-Cruz; M Carla Cabrera; Maram Alotaiby; Anne M Miermont; Anna T Riegel; Priscilla A Furth
Journal:  Mol Endocrinol       Date:  2011-02-03

7.  Cytokine and progesterone receptor interplay in the regulation of MUC1 gene expression.

Authors:  Neeraja Dharmaraj; Peng Wang; Daniel D Carson
Journal:  Mol Endocrinol       Date:  2010-10-20

8.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

9.  Pathobiological implications of MUC16 expression in pancreatic cancer.

Authors:  Dhanya Haridas; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Satyanarayana Rachagani; Eric Cruz; Sushil Kumar; Srustidhar Das; Subodh M Lele; Judy M Anderson; Uwe A Wittel; Michael A Hollingsworth; Surinder K Batra
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

10.  Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.

Authors:  Parama Dey; Moorthy P Ponnusamy; Shonali Deb; Surinder K Batra
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

View more
  19 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

3.  Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival.

Authors:  S Joshi; S Kumar; M P Ponnusamy; S K Batra
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 5.  Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.

Authors:  Ying Xie; Yazhe Wang; Jing Li; Yu Hang; David Oupický
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 6.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.

Authors:  Shailendra K Gautam; Sushil Kumar; Andrew Cannon; Bradley Hall; Rakesh Bhatia; Mohd Wasim Nasser; Sidharth Mahapatra; Surinder K Batra; Maneesh Jain
Journal:  Expert Opin Ther Targets       Date:  2017-05-29       Impact factor: 6.902

7.  Neutrophil Gelatinase-Associated Lipocalin Protects Acinar Cells From Cerulein-Induced Damage During Acute Pancreatitis.

Authors:  Rakesh Bhatia; Sakthivel Muniyan; Christopher M Thompson; Sukhwinder Kaur; Maneesh Jain; Rakesh K Singh; Amaninder Dhaliwal; Jesse L Cox; Shizuo Akira; Shailender Singh; Surinder K Batra; Sushil Kumar
Journal:  Pancreas       Date:  2020 Nov/Dec       Impact factor: 3.327

8.  Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.

Authors:  Suhasini Joshi; Eric Cruz; Satyanarayana Rachagani; Sushovan Guha; Randall E Brand; Moorthy P Ponnusamy; Sushil Kumar; Surinder K Batra
Journal:  Mol Oncol       Date:  2016-04-29       Impact factor: 6.603

9.  Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis.

Authors:  Yan Wang; Sushil Kumar; Satyanarayana Rachagani; Balasrinivasa R Sajja; Ying Xie; Yu Hang; Maneesh Jain; Jing Li; Michael D Boska; Surinder K Batra; David Oupický
Journal:  Biomaterials       Date:  2016-05-27       Impact factor: 12.479

10.  The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma.

Authors:  Priya Pai; Satyanarayana Rachagani; Imayavaramban Lakshmanan; Muzafar A Macha; Yuri Sheinin; Lynette M Smith; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Mol Oncol       Date:  2015-10-19       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.